Biocon Acquires 26.19 Crore Shares of Biocon Biologics

Biocon Limited has finalized the acquisition of 26,19,17,480 equity shares of its unlisted subsidiary, Biocon Biologics Limited (BBL). This acquisition was completed through transactions with Mylan Inc., Serum Institute Life Sciences Private Limited, Tata Capital Growth Fund II, and Activ Pine LLP. Concurrently, Biocon issued and allotted 17,12,79,553 equity shares to these entities on a preferential basis, as part of the consideration for the acquisition. The shares were issued at an issue price of Rs. 405.78 per share, following the approval of the Fund Raising Committee.

The financial terms of the transaction included the issuance of Biocon shares with a face value of Rs. 5 each. The total issued, subscribed, and paid-up equity share capital of Biocon increased from Rs. 668.48 crore to Rs. 754.12 crore. This increase resulted from the allotment of new shares, raising the total number of fully paid-up equity shares to 1,50,82,43,188. Additionally, Biocon completed the acquisition of 7,18,34,691 BBL shares from Mylan for a cash consideration of USD 200 million, as part of a larger transaction approved by the Board.

The scope of this acquisition involved a share swap and purchase agreement with the aforementioned entities. The equity shares allotted to the allottees will rank pari-passu with the existing equity shares of Biocon. The acquisition of BBL shares from Mylan, Serum Institute, Tata Capital, and Activ Pine LLP was executed to consolidate Biocon’s holding in its subsidiary, enhancing its control over BBL’s operations and strategic direction.

Following the completion of these transactions, Biocon now holds approximately 94% of the paid-up equity share capital of BBL on a fully diluted basis. This acquisition aligns with Biocon’s strategic objectives to strengthen its position in the biologics sector. The transactions were conducted in accordance with the SEBI (Issue of Capital Disclosure Requirements) Regulations, 2018, ensuring compliance with regulatory standards.

The timeline for the acquisition process included an extra-ordinary general meeting of Biocon’s shareholders on December 31, 2025, where the proposal was approved. The Fund Raising Committee meeting, which finalized the share issuance, commenced at 09:15 PM and concluded at 09:30 PM on January 5, 2026. The acquisition was executed following in-principle approvals from the National Stock Exchange of India Limited and BSE Limited, dated December 31, 2025.

Biocon Limited is a leading biopharmaceutical company focused on innovation and development in the biologics sector. The company prioritizes expanding its portfolio in biosimilars and novel biologics, aiming to address global healthcare challenges through affordable and accessible solutions. Biocon continues to enhance its capabilities and market presence through strategic acquisitions and collaborations.